RxDoctor Payments Data

Inchol Yun

Family Medicine · Dacula, GANPI 1740332840

Payments from drug & device makers

$13,891in general payments, 2019–2025

Across 675 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Pfizer$1K
  • Amgen$1K
  • AstraZeneca$990
  • Lilly USA, LLC$943
  • AbbVie$782
  • plus $6K from 45 others

What the payments were for

  • Speaking & faculty fees$5004%
  • Food & beverage$13,38096%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,891 in reported general payments places this provider in the 95th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$129,611
Medicare patients
329
Services billed
3,114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide85$106,055
JardianceEmpagliflozin47$66,446
EliquisApixaban56$50,209
FarxigaDapagliflozin Propanediol26$33,298
MounjaroTirzepatide24$31,962
TrulicityDulaglutide24$31,486
XareltoRivaroxaban29$29,581
JanuviaSitagliptin Phosphate15$17,084
RestasisCyclosporine17$14,615
Breo ElliptaFluticasone/Vilanterol29$11,620
EntrestoSacubitril/Valsartan15$10,197
TradjentaLinagliptin11$8,018
MyrbetriqMirabegron11$4,942
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,353
Novolog FlexpenInsulin Aspart11$3,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,766$106,05585 claims
Boehringer IngelheimJardiance, Tradjenta$411$74,46458 claims
Lilly USA, LLCMounjaro, Trulicity$943$63,44748 claims
PfizerEliquis$1,202$50,20956 claims
AstraZenecaFarxiga$990$33,29826 claims
MerckJanuvia$318$17,08415 claims
AbbVieRestasis, Synthroid$782$16,68950 claims
GSKBreo Ellipta, Shingrix$353$15,97349 claims
NovartisEntresto$34$10,19715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Dacula

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →